PEGylation in anti-cancer therapy: An overview

被引:1
|
作者
Prajna Mishra
Bismita Nayak
R.K.Dey
机构
[1] Centre for Applied Chemistry, Central University of Jharkhand
[2] Department of Life Science, National Institute of Technology
关键词
D O I
暂无
中图分类号
R943 [制剂学];
学科分类号
100602 ; 100702 ;
摘要
Advanced drug delivery systems using poly(ethylene glycol)(PEG) is an important development in anti-cancer therapy. PEGylation has the ability to enhance the retention time of the therapeutics like proteins, enzymes small molecular drugs, liposomes and nanoparticles by protecting them against various degrading mechanisms active inside a tissue or cell, which consequently improves their therapeutic potential. PEGylation effectively alters the pharmacokinetics(PK) of a variety of drugs and dramatically improves the pharmaceutical values;recent development of which includes fabrication of stimuli-sensitive polymers/smart polymers and polymeric micelles to cope of with the pathophysiological environment of targeted site with less toxic effects and more effectiveness. This overview discusses PEGylation involving proteins, enzymes, low molecular weight drugs, liposomes and nanoparticles that has been developed, clinically tried for anti-cancer therapy during the last decade.
引用
收藏
页码:337 / 348
页数:12
相关论文
共 50 条
  • [1] PEGylation in anti-cancer therapy: An overview
    Mishra, Prajna
    Nayak, Bismita
    Dey, R. K.
    [J]. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 11 (03) : 337 - 348
  • [2] PEGylation of conjugated linoleic acid and its application as an anti-cancer prodrug
    Seo, Ji-Hye
    Moon, Hyun-Seuk
    Guo, Ding-Ding
    Lee, Hong-Goo
    Choi, Yun-Jaie
    Cho, Chong-Su
    [J]. ASBM7: ADVANCED BIOMATERIALS VII, 2007, 342-343 : 441 - +
  • [3] Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
    Crisci, Stefania
    Amitrano, Filomena
    Saggese, Mariangela
    Muto, Tommaso
    Sarno, Sabrina
    Mele, Sara
    Vitale, Pasquale
    Ronga, Giuseppina
    Berretta, Massimiliano
    Di Francia, Raffaele
    [J]. MEDICINA-LITHUANIA, 2019, 55 (08):
  • [4] The microbiome in anti-cancer therapy
    Bashiardes, Stavros
    Tuganbaev, Timur
    Federici, Sara
    Elinav, Eran
    [J]. SEMINARS IN IMMUNOLOGY, 2017, 32 (0C) : 74 - 81
  • [5] microRNAs as Anti-Cancer Therapy
    Garofalo, Michela
    Di Leva, Gianpiero
    Croce, Carlo M.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (33) : 5328 - 5335
  • [6] An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management
    Smith, Padraic
    Lavery, Anita
    Turkington, Richard C.
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2020, 48-49
  • [7] Anti-cancer therapy success
    Wong, JF
    [J]. GENETIC ENGINEERING NEWS, 2005, 25 (11): : 48 - 49
  • [8] PHARMACOGENETICS OF ANTI-CANCER THERAPY
    van Schaik, Ron H. N.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S49 - S49
  • [9] Viral anti-cancer therapy
    Blazejewska, Paulina
    Gozdzicka-Jozefiak, Anna
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (07): : 279 - 283
  • [10] Resveratrol: An overview of its anti-cancer mechanisms
    Elshaer, Mohamed
    Chen, Yeru
    Wang, Xiu Jun
    Tang, Xiuwen
    [J]. LIFE SCIENCES, 2018, 207 : 340 - 349